Responsible for managing the business of Atos products all over Cairo and managing Cairo team who accountable for almost 5 Millions EGP annually for 2 Senior Med. Reps. and 6 Med. Reps. In the GIT, INT, ENT, Paediatric, Ortho marketing.
Moreover, managing the business for Oncology product with outsource company on daily bases to confirm implementing our strategy with their field force activities to achieve our target and objectives.
In 2012 take the responsibilities for building Oncology team and identify our customers.
Starting the company new business in the biggest Hospitals like Arab Contractors H. Egypt Air H. Maadi Military H. Kobbry Elkoba Military H.
Exceed the sales plan for 2013 by 15%.
Gaining 10% marketing growth for 2013 over previous year.
Successfully launching Micardis in Riyadh in private and institutional hosp. And achieve
our sales plan with 24% market share.
Exceeding the sales plan for 2002 by 10%.
Responsible for handling big customers and the main chain pharmacies in Riyadh with 20% sales growth YTD.
Successfully coded the core products in assigned private hospitals and polyclinics such as Insurance H. Mowassat H., Hammadi H., Mashary H. And Dar Alhekm. And in Military H. Such as Alkaada H.
Best sales performance of Spiriva, 2005 among the Gulf region.
Rewarded as the best achiever at institutional team in 2000.
As the 1st time, Introduce Vancocin Inj. In assigned Hosp. Such as Sednawy Insurance H. which increase the total company sales by 40% over the sales plan in 2000.
By the beginning of 2001, increase the company responsibilities by taken the sales responsibilities for Nasser Institute H. Which considered as the biggest Institutional H. In Cairo beside my main duties.
Successfully exceed the sales plan by 50% in 2001.
Achieving the sales plan for 1999 by 15% marketing growth over the previous year. Starting the Company new business in some private H. Such as Italian H., Greece H. And Elkebty H. Increase the SOV for Ceclor SR, Keflex, and Nebsin in assigned territory with 25% market share.